166 related articles for article (PubMed ID: 17324475)
1. Schizophrenia as a GSK-3 dysregulation disorder.
Lovestone S; Killick R; Di Forti M; Murray R
Trends Neurosci; 2007 Apr; 30(4):142-9. PubMed ID: 17324475
[TBL] [Abstract][Full Text] [Related]
2. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.
Freyberg Z; Ferrando SJ; Javitch JA
Am J Psychiatry; 2010 Apr; 167(4):388-96. PubMed ID: 19917593
[TBL] [Abstract][Full Text] [Related]
3. [Schizophrenia, neurodevelopment and glycogen synthase kinase-3].
Nadri C; Kozlovsky N; Agam G
Harefuah; 2003 Sep; 142(8-9):636-42, 644. PubMed ID: 14518171
[TBL] [Abstract][Full Text] [Related]
4. GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
Kozlovsky N; Belmaker RH; Agam G
Eur Neuropsychopharmacol; 2002 Feb; 12(1):13-25. PubMed ID: 11788236
[TBL] [Abstract][Full Text] [Related]
5. An emerging role for Wnt and GSK3 signaling pathways in schizophrenia.
Singh KK
Clin Genet; 2013 Jun; 83(6):511-7. PubMed ID: 23379509
[TBL] [Abstract][Full Text] [Related]
6. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
Sutton LP; Rushlow WJ
Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
[TBL] [Abstract][Full Text] [Related]
7. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
Ivanova SA; Losenkov IS; Bokhan NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
Manduca JD; Thériault RK; Perreault ML
Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
[TBL] [Abstract][Full Text] [Related]
9. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity.
Benedetti F; Poletti S; Radaelli D; Bernasconi A; Cavallaro R; Falini A; Lorenzi C; Pirovano A; Dallaspezia S; Locatelli C; Scotti G; Smeraldi E
Genes Brain Behav; 2010 Jun; 9(4):365-71. PubMed ID: 20113358
[TBL] [Abstract][Full Text] [Related]
10. GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.
Tang H; Shen N; Jin H; Liu D; Miao X; Zhu LQ
Mol Neurobiol; 2013 Dec; 48(3):404-11. PubMed ID: 23440732
[TBL] [Abstract][Full Text] [Related]
11. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
Amar S; Belmaker RH; Agam G
Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3 regulation of chromatin segregation and cytokinesis in mouse preimplantation embryos.
Acevedo N; Wang X; Dunn RL; Smith GD
Mol Reprod Dev; 2007 Feb; 74(2):178-88. PubMed ID: 16941690
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
14. Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment.
Ferreira AS; Raposo NR; Sallet PC; Van de Bilt MT; Machado-Vieira R; Talib LL; Gattaz WF
Eur Arch Psychiatry Clin Neurosci; 2015 Mar; 265(2):167-70. PubMed ID: 24831601
[TBL] [Abstract][Full Text] [Related]
15. Activator or inhibitor? GSK-3 as a new drug target.
Takahashi-Yanaga F
Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
[TBL] [Abstract][Full Text] [Related]
16. Focusing the spotlight on GSK-3 in aging.
Zhou J; Force T
Aging (Albany NY); 2013 Jun; 5(6):388-9. PubMed ID: 23804600
[No Abstract] [Full Text] [Related]
17. The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle.
Ryves WJ; Harwood AJ
Prog Cell Cycle Res; 2003; 5():489-95. PubMed ID: 14593744
[TBL] [Abstract][Full Text] [Related]
18. Genetic correlational analysis of glycogen synthase kinase-3 beta and prepulse inhibition in inbred mice.
Amar S; Jones BC; Nadri C; Kozlovsky N; Belmaker RH; Agam G
Genes Brain Behav; 2004 Jun; 3(3):178-80. PubMed ID: 15140013
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum.
Alimohamad H; Rajakumar N; Seah YH; Rushlow W
Biol Psychiatry; 2005 Mar; 57(5):533-42. PubMed ID: 15737669
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism.
MacAulay K; Doble BW; Patel S; Hansotia T; Sinclair EM; Drucker DJ; Nagy A; Woodgett JR
Cell Metab; 2007 Oct; 6(4):329-37. PubMed ID: 17908561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
